GB2236751B — Heterocyclic compounds
Assigned to John Wyeth and Brother Ltd · Expires 1993-04-28 · 33y expired
What this patent protects
Compounds of formula <IMAGE> wherein R1 is hydrogen or one or more specified substituents, X is -O- or -NR2- where R2 is lower alkyl, lower alkenyl, lower alkynyl, aryl or specified substituted lower alkyl or R2 represents a group -Z- which is connected to the 8-positio…
USPTO Abstract
Compounds of formula <IMAGE> wherein R1 is hydrogen or one or more specified substituents, X is -O- or -NR2- where R2 is lower alkyl, lower alkenyl, lower alkynyl, aryl or specified substituted lower alkyl or R2 represents a group -Z- which is connected to the 8-position of the aromatic ring so as to form a heterocyclic ring of 5 to 7 ring members, Y is O or NR3 where R3 is hydrogen or lower alkyl, and B is a saturated azabicyclic ring (e.g. tropanyl or quinuclidinyl) or a N-oxide thereof and their acid addition salts are 5-HT3 antagonists which may be used in, for example, the treatment of neuro-psychiatric disorders.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.